MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 39.37% | -7.74% | 29.52% | -30.75% | 36.50% |
| Total Depreciation and Amortization | 5.53% | -28.90% | -8.84% | 11.20% | 14.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -198.38% | -12.50% | 5.47% | 80.83% | 152.09% |
| Change in Net Operating Assets | -8.89% | 253.19% | -207.30% | -82.90% | 138.51% |
| Cash from Operations | -57.03% | 58.64% | -3.69% | -204.48% | 144.96% |
| Capital Expenditure | -29.75% | 40.83% | -162.18% | 82.17% | 54.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -96.22% | 209.63% | -90.78% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -29.75% | 5.47% | -106.57% | -87.70% | 158.51% |
| Total Debt Issued | -100.00% | -93.32% | -- | -- | -- |
| Total Debt Repaid | 85.30% | -1,398.04% | 43.12% | 31.20% | -0.77% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 295.00% | -77.53% | -56.16% | 35.33% | 68.54% |
| Cash from Financing | 89.30% | -425.43% | 1,121.63% | 72.33% | 20.55% |
| Foreign Exchange rate Adjustments | -354.55% | -13.73% | 71.91% | 102.37% | -623.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.88% | -211.06% | 12.68% | -121.16% | 376.79% |